Пишут, что

[bbb]

https://enlivex.com/investor-relations
https://www.globenewswire.com/search/keyword/enlivex

Nes Ziona, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE)

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage immunotherapy company, today reported positive top-line results of an investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe/critical condition.

The clinical trial included five COVID-19 patients, three in severe condition and two in critical condition. All five patients had complete recovery from their respective severe/critical condition and were released from the hospital after an average of 5.5 days (severe) and 8.5 days (critical), following administration of Allocetra, at which time they were all COVID-19 PCR negative. There were no reported severe adverse events relating to the administration of Allocetra in the patients, and the therapy was well-tolerated.

https://www.enlivex.com/investor-relations/#latest-news
https://www.pressviewer.com/profiles/investor/NewsPrint.asp?v=7&b=2380&ID=93761&m=rl
https://www.globenewswire.com/Search?organization=Enlivex%20Therapeutics%20Ltd

АПДЕЙТ: Запустили вторую фазу испытаний
https://clinicaltrials.gov/ct2/show/NCT04590053

АПДЕЙТ-2: Первые два пациента получили препарат
https://www.pressviewer.com/profiles/investor/NewsPrint.asp?v=7&b=2380&ID=93966&m=rl
https://s3.amazonaws.com/b2icontent.irpass.cc/2380/rl93966.pdf

АПДЕЙТ-3 - 3 декабря
https://www.pressviewer.com/profiles/investor/NewsPrint.asp?b=2380&ID=95434&m=rl

Allocetra-OTS in COVID-19, Phase II
https://clinicaltrials.gov/ct2/show/NCT04590053
https://clinicaltrials.gov/ct2/history/NCT04590053

АПДЕЙТ-4 - 3 февраля
https://www.globenewswire.com/news-release/2021/02/03/2168999/0/en/Enlivex-Reports-Positive-Top-Line-Results-from-Phase-II-Clinical-Trial-Evaluating-Allocetra-in-Severe-and-Critical-COVID-19-Patients-and-Provides-a-Program-Update.html

АПДЕЙТ-5 - запущена IIb фаза испытаний

https://clinicaltrials.gov/ct2/show/NCT04513470
https://clinicaltrials.gov/ct2/show/NCT04922957

August 15, 2021
Enlivex: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of a Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
https://www.globenewswire.com/news-release/2021/08/15/2280766/0/en/Enlivex-After-Review-of-Phase-II-Data-Israeli-Ministry-of-Health-Authorizes-Initiation-of-a-Multi-Center-Randomized-Phase-IIb-Clinical-Trial-Evaluating-Allocetra-in-Severe-and-Crit.html

September 22, 2021
Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS
https://www.globenewswire.com/news-release/2021/09/22/2301123/0/en/Enlivex-Doses-First-Patient-in-Placebo-Controlled-Phase-IIb-Clinical-Trial-Evaluating-Allocetra-in-Severe-and-Critical-COVID-19-Patients-with-ARDS.html

November 04, 2021
Spanish Regulator Grants Enlivex Authorization To Expand Its Sepsis Phase II into Spain
https://www.globenewswire.com/news-release/2021/11/04/2327468/0/en/Spanish-Regulator-Grants-Enlivex-Authorization-To-Expand-Its-Sepsis-Phase-II-into-Spain.html

November 10, 2021
Spanish Regulator Grants Enlivex Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into Spain
https://www.globenewswire.com/news-release/2021/11/10/2331506/0/en/Spanish-Regulator-Grants-Enlivex-Authorization-to-Expand-its-Phase-IIb-Trial-Evaluating-Allocetra-in-Severe-and-Critical-COVID-19-Patients-into-Spain.html